Company intelligence / Profile preview

Mote Therapeutics

Lexington, Massachusetts, United Statesmonterosatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Mote Therapeutics has developed an extrahepatic targeted mRNA delivery platform that enables active targeting of nanoparticles to specific cells while preventing uptake by unintended targets. The technology has demonstrated efficacy in animal models but no clinical trial results are reported yet[1].

Therapeutic areas: Other
Modalities: mRNANanoparticle-based delivery systems
Industry: Biotech

Beyond the preview

Go deeper on Mote Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mote Therapeutics.

Explore the full profile